<DOC>
	<DOCNO>NCT02639858</DOCNO>
	<brief_summary>A phase II study evaluate efficacy safety Docetaxel-PM recurrent metastatic head neck squamous cell carcinoma</brief_summary>
	<brief_title>Study Evaluate Efficacy Safety Docetaxel Polymeric Micelle ( PM ) Recurrent Metastatic HNSCC</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>1 . Patients histologically cytologically diagnosed oral cavity , oropharynx , hypopharynx , larynx squamous cell carcinoma recurrent metastatic evidence treat salvage surgery radiotherapy 2 . Time disease progression , regardless whether treatment platinumbased therapy ①Patients disease progression concurrent chemoradiotherapy curative purpose ( include induction chemotherapy ) include platinumbased ( cisplatin carboplatin ) chemotherapy ② Patients disease progression primary secondary treatment palliative purpose include platinumbased ( cisplatin carboplatin ) chemotherapy 3 . Patients age 20 year old 79 year old 4 . Patients whose Eastern Cooperative Oncology Group ( ECOG ) performance score 02 5 . Patients one measurable lesion least RECIST criteria 1.1 6 . Patients show adequate function organ : bone marrow : Absolute Neutrophil count ( ANC ) ≥ 1,500/μL , Platelet count ≥ 100,000/μ , Hb≥ 9.0 g/dl ( allow blood transfusion ) Liver : ① evidence liver metastasis ; Total bilirubin ≤ 1.5mg/dl , alkaline phosphatase ( ALP ) , aspartate transaminase ( AST ) , alanine transaminase ( ALT ) ≤ 2.0 X upper limit normal ( ULN ) ② liver metastasis ; bilirubin ≤ 3.0 X ULN , aspartate transaminase ( AST ) , alanine transaminase ( ALT ) ≤ 5.0 X ULN Kidney : creatinine ≤ 1.5 X ULN 7 . Patients sign write consent form prior participation clinical trial 1 . Patients Primary tumor nasopharynx 2 . Patients receive treatment prior regimen three drug 3 . Patients Primary malignant tumor site ( except ; early cervical cancer , skin basal cell cancer receive appropriate treatment , Malignant tumor without recurrent state treat five year previously ) 4 . Previous radiotherapy allow , patient complete radiotherapy 4 week prior initial administration investigational product 5 . Patients receive major surgery within 4 week prior initial administration investigational product patient recover major surgery 6 . Patients severe disease medical condition follow Congestive heart failure ( NYHA class III IV ) Unstable angina , cardiac infarction within 6 month Seconddegree atrioventricular ( AV ) block , clinically cardiac arrhythmia need drug therapy Uncontrollable Hypertension Hepatic cirrhosis ( ≥ Child class B ) Interstitial lung disease Mental disorder comply protocol Uncontrolled diabetes Uncontrolled ascites pulmonary edema Active infection 7 . Pregnant lactate woman 8 . Patients consider inappropriate participate study investigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>